Generate a tailored SOP for Dr. Dunhui Li. Improve your application with a focused, well-structured draft.
Dunhui Li is an Associate Research Scientist in the Department of Neurology at Yale School of Medicine, focusing on the development of antisense oligonucleotide therapies for neurological conditions, particularly Parkinson's disease. He completed his medical education and postgraduate training in China from 2008 to 2016 and has since moved to Australia to enter the field of molecular genetics therapeutics. Dr. Li has worked with pioneers in the field, such as Professors Steve Wilton and Sue Fletcher, contributing to the development of FDA-approved antisense drugs for Duchenne muscular dystrophy. His doctoral research, conducted from 2016 to 2021, was centered on creating antisense oligonucleotide treatments for Parkinson's disease. His work has led to a patent application licensed by the Perron Institute and Black Swan Pharmaceuticals, focusing on innovative genetic therapy for Parkinson's disease. Dr. Li joined the Adams Center at Yale in November 2024, where he is leading efforts to develop precise and effective therapies for this condition.
Yale School of Medicine • New Haven, CT, USA
Leading research efforts in developing therapies for Parkinson's disease.
Patented application for a novel genetic therapy targeting Parkinson's disease.
Administered via the Graduate School of Arts and Sciences (GSAS). GRE General is optional for PhD.